Armistice Capital LLC Buys New Position in Helius Medical Technologies, Inc. (NASDAQ:HSDT)

Armistice Capital LLC bought a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 130,000 shares of the company’s stock, valued at approximately $127,000.

Helius Medical Technologies Stock Down 6.0 %

Shares of HSDT opened at $0.68 on Friday. The company has a market cap of $2.42 million, a P/E ratio of -0.05 and a beta of 1.61. Helius Medical Technologies, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $9.89. The firm’s 50 day moving average price is $0.77 and its 200 day moving average price is $2.21.

Helius Medical Technologies (NASDAQ:HSDT) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.14). The company had revenue of $0.18 million for the quarter. Helius Medical Technologies had a negative return on equity of 258.06% and a negative net margin of 1,487.54%. During the same quarter in the prior year, the company earned ($3.00) earnings per share.

Helius Medical Technologies Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.